Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis
Φόρτωση...
Ημερομηνία
Συγγραφείς
Makis, A. C.
Galanakis, E.
Hatzimichael, E. C.
Papadopoulou, Z. L.
Siamopoulou, A.
Bourantas, K. L.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
J Infect
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVES AND METHODS: Brucellosis is characterized by chronicity and relapses despite efficacious treatment. Cytokines and especially the Th1/Th2 balance may be involved in the susceptibility or resistance to the Brucella species. In order to identify predictors of treatment outcome, we measured the pre and posttreatment levels of serum interleukin-2 (IL-2) and soluble IL-2 receptor alpha (sIL-2Ralpha) in 20 children with brucellosis. All children were treated for 6 weeks and three of them (15%) presented with a relapse at 2, 3 and 8 months after treatment had ended. RESULTS: Serum IL-2 levels, both pretreatment and posttreatment, did not significantly differ between patients and controls. By contrast, pretreatment sIL-2Ralpha levels were significantly higher in patients (P< or =0.0001) than in controls. sIL-2Ralpha levels significantly declined (P<0.001) after the 6-week antibiotic regimen in the 17 children who subsequently had a good outcome without relapses, but not in the three patients who relapsed. CONCLUSIONS: A decline in serum sIL-2Ralpha levels might be used as a marker of treatment efficacy in brucellosis.
Περιγραφή
Λέξεις-κλειδιά
Anti-Infective Agents/administration & dosage/therapeutic use, Brucellosis/*drug therapy/microbiology, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Interleukin-2/blood, Interleukin-2 Receptor alpha Subunit, Male, Predictive Value of Tests, Receptors, Interleukin-2/*blood, Rifampin/administration & dosage/therapeutic use, Solubility, Treatment Outcome, Trimethoprim-Sulfamethoxazole Combination/administration & dosage/therapeutic use
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/16230217
http://ac.els-cdn.com/S0163445304002506/1-s2.0-S0163445304002506-main.pdf?_tid=1072c899c9a0960ea48e1da7a8ba6a4a&acdnat=1337334736_29e30d265f4f1cf856ecad065e4aa949
http://ac.els-cdn.com/S0163445304002506/1-s2.0-S0163445304002506-main.pdf?_tid=1072c899c9a0960ea48e1da7a8ba6a4a&acdnat=1337334736_29e30d265f4f1cf856ecad065e4aa949
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής